MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.40
-0.10
-1.18%
Closed 16:00 02/27 EST
OPEN
8.21
PREV CLOSE
8.50
HIGH
8.50
LOW
8.02
VOLUME
26.60K
TURNOVER
--
52 WEEK HIGH
13.50
52 WEEK LOW
4.650
MARKET CAP
84.49M
P/E (TTM)
-81.6327
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BVXV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BVXV stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.

EPS

BVXV News

More
  • UPDATE: BiondVax Says Prelim. Data Indicates Both Primary Objectives For Phase 2 Trial Met
  • Benzinga · 02/05 18:02
  • BoindVax Pharma Reports Prelim. Data From Phase 2 Trial Of M-001 Universal Flu Vaccine Candidate
  • Benzinga · 02/05 18:01
  • Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
  • PR Newswire · 02/05 18:00
  • BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
  • PR Newswire · 01/16 20:05

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About BVXV

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
More

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.